

Medicare Part B Drugs and Biologicals

10/27/2022



Today's Presenters

- Jennifer Lee
 - Provider Outreach and Education Consultant
- Jennifer DeStefano
 - Provider Outreach and Education Consultant

Disclaimer

National Government Services, Inc. has produced this material as an informational reference for providers furnishing services in our contract jurisdiction. National Government Services employees, agents, and staff make no representation, warranty, or guarantee that this compilation of Medicare information is error-free and will bear no responsibility or liability for the results or consequences of the use of this material. Although every reasonable effort has been made to assure the accuracy of the information within these pages at the time of publication, the Medicare Program is constantly changing, and it is the responsibility of each provider to remain abreast of the Medicare Program requirements. Any regulations, policies and/or guidelines cited in this publication are subject to change without further notice. Current Medicare regulations can be found on the [CMS website](#).

No Recording

- Attendees/providers are **never** permitted to record (tape record or **any** other method) our educational events
- This applies to our webinars, teleconferences, live events and any other type of National Government Services educational events

Objectives

- To gain an understanding of the current policies and billing guidelines for drugs and biologicals

Agenda

- Medicare Part B Coverage
- Self-Administered Drugs
- Pricing and Reimbursement
- Vaccinations and Administrations
- Clinical Trial Drugs and Biologicals
- Not Otherwise Classified & Compound Drugs
- Units of Service
- Discarded Drugs
- Patient Supplied or Free-of-Charge Drugs

Medicare Part B Coverage

Medicare Part B Coverage - Drugs and Biologicals

- Drugs and biologicals are covered only if all following requirements are met
 - Meet definition of drugs and biologicals
 - Meet all general requirements for covered items as incident to physician's service
 - Reasonable and necessary for diagnosis or treatment of illness or injury for which are administered
 - Type that are not usually self-administered
 - Not excluded as noncovered immunizations
 - Not been determined by FDA to be less than effective
- [CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 50](#)

Medicare Part B Coverage

- Antigens
 - CPT codes 95144-95165 are only considered when the antigens are
 - Prepared by a physician who is a doctor of medicine or osteopathy and has examined the patient, determined a plan of treatment and dosage regimen
 - Determined by CMS a reasonable supply of antigens, not more than a 12 month supply prepared at any one time
 - The incident-to rule and regulations do not apply
- [CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 50.4.4.1](#)

Medicare Part B Coverage

- Blood clotting factors
 - Medicare provides coverage of self-administered blood clotting factors for hemophilia patients who are competent to use such factors to control bleeding without medical supervision
- MLN Matters® [MM10474 Revised: Diagnosis Code Update for Add-on Payments for Blood Clotting Factor Administered to Hemophilia Inpatients](#)

Medicare Part B Coverage

- Drugs used with DME
 - Medicare covers drugs infused through DME, such as an infusion pump or drugs given by a nebulizer
- [Practitioners: Are You Ordering Nebulizers and Inhalation Medication for Your Patient?](#)

Medicare Part B Coverage

- Erythropoiesis Stimulating Agent (ESA)
 - Not reasonable and necessary for beneficiaries with certain clinical conditions
 - Damaging effect of the ESA on their underlying disease
 - The underlying disease increases their risk of adverse effects related to ESA use
 - [NCD 110.21: Erythropoiesis Stimulating Agents \(ESAs\) in Cancer and Related Neoplastic Conditions](#)

Medicare Part B Coverage

- Enteral and Parenteral Nutrition Therapy
 - Prosthetic benefit for individuals with “permanent” dysfunction of the digestive tract. If medical record, including the judgment or the attending physician, indicates that the impairment will be long and indefinite duration, the test of permanence is met
 - [NCD 180.2: Enteral and Parenteral Nutritional Therapy](#)

Medicare Part B Coverage

- Injectable and infused drugs
- Covered when given by a licensed medical provider
 - CPT codes include chemotherapy infusions and injections, therapeutic, prophylactic, and diagnostic infusions/injections, and hydration
 - The start and stop times must be evident in the documentation in order to bill units for hours infused
 - The use of a doctor's order or pharmacy directive/label to calculate times is not appropriate as correct coding is based on how incidents/services occur; not how services are planned
 - [Chemotherapy General Infusion Information](#)

Medicare Part B Coverage

- Injectable osteoporosis drugs
 - LCD [L37535](#) - Vitamin D Assay Testing
- Oral anti-nausea drugs
 - The drugs must meet both these conditions
 - Be administered immediately before, at, or within 48 hours after chemotherapy
 - Be used as a full therapeutic replacement for an intravenous anti-nausea drugs
- [CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 50.5.4](#)

Medicare Part B Coverage

- Intravenous Immune Globulin
 - The dose and frequency of administration should be consistent with the FDA approved package insert
 - When different from the FDA approved package insert, literature to support the specific schedule chosen should be available
 - Claims for procedures performed at unusually frequent intervals/high dosages may be reviewed for medical necessity
 - If coverage of IVIG is denied, the administration and pre-administration services associated with IVIG will also be denied
- [LCD Article A52446: Billing and Coding: Intravenous Immune Globulin \(IVIG\)](#)

Medicare Part B Coverage

- Oral ESRD drugs
 - Medicare helps pay for some oral ESRD drugs if
 - The same drug is available in injectable form and
 - The drug is covered under the Part B ESRD benefit
 - [CMS IOM Publication 100-04, Medicare Claims Processing Manual, Chapter 8](#)
- Oral cancer drugs
 - One of the following must apply
 - The same drug is available in injectable form, or
 - The drug is a prodrug of the injectable or oral form
 - [CMS IOM Publication 100-04, Medicare Claims Processing Manual, Chapter 17, Section 80.1](#)

Medicare Part B Coverage

- Transplant drugs
 - These drugs are not billable to Medicare Part B
 - Medicare covers prescription drugs used in immunosuppressive therapy under the DME benefit if they meet specific criteria
 - Unless the transplant occurred prior to Medicare Part A enrollment; may be eligible for coverage under Medicare Part D
- [CMS IOM Publication 100-04, *Medicare Claims Processing Manual*, Chapter 17, Section 80.3](#)

Pricing and Reimbursement

Drug Pricing

- CMS prices drugs based on Average Sales Price
 - ASP files are updated by CMS quarterly
 - [Medicare Part B Drug Average Sales Price](#)

Note: NOC and compound drugs not listed on ASP files are priced by MAC

Wholesale Acquisition Cost/Invoice Pricing

- Payment allowance limits for drugs and biologicals that are not included in ASP or NOC files are based on published WAC and includes invoice pricing
- NGS has the discretion to determine how many invoices are necessary to determine reimbursement amounts for drugs subject to invoice pricing

- Separate invoice for each claim

OR

- Establish payment amounts based on a smaller number of invoices that are representative of providers' costs

Assignment Required

- Payment for drugs and biologicals covered under Medicare Part B is made on an assignment basis
 - All claims processed as assigned
- Patients can only be billed for applicable Medicare Part B deductible and coinsurance amounts
- [CMS IOM, Publication 100-04, *Medicare Claims Processing Manual*, Chapter 17, Section 50](#)

Medicare Part B Vaccinations and Administration

Vaccinations and Administration

- G0008 – Influenza Administration Code
 - [Influenza Virus Vaccine and Administration](#)
- G0009 – Pneumococcal Administration Code
 - [Pneumococcal Vaccine and Administration](#)
- G0010 – Hepatitis B Administration Code
 - [Hepatitis B Virus Vaccine and Administration](#)
- [CMS IOM, Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 50.4.4.2](#)

COVID-19 Administration

- When COVID-19 vaccine doses are provided by the government without charge, only bill for the vaccine administration
- Do not include the vaccine codes on the claim when the vaccines are free
 - [COVID-19 Vaccine and Monoclonal Antibody](#)

General Coding Facts

- The drug code and drug administration code must be submitted on the same claim
 - Exception – COVID-19
- Procedure codes may be subject to NCCI
- Claim(s) submitted without valid ICD-10-CM diagnosis code will be returned to provider as incomplete
- Diagnosis code(s) must best describe the patient's condition for which the service was performed

Clinical Trial Drugs and Biologicals

Clinical Trial Drugs and Biologicals

- A clinical trial is an interventional study where treatment is evaluated by qualified researchers who have developed an approved protocol
 - Interventions include both diagnostic and therapeutic services
 - The administration of drugs included in a clinical trial may be covered by Medicare Part B
- [Clinical Trial Services and Modifiers Q0 and Q1](#)

Proper Billing for Clinical Drugs/Biologicals

| 1500 Claim Field | ANSI 837 v5010 Loop & Segment | Information Required |
|--------------------|-------------------------------|---|
| 24D | 2400, SV101-2 | HCPCS code for clinical trial drug |
| 24D (line 2) | 2400, SV101-2 | Administration code |
| 24D (line 1 and 2) | 2400, SV101-3 | Q0 Modifier - <i>must be appended to both admin and drug code</i> |
| 28 (line 1) | 2300, CLM01 | Total charge for drug code = \$0.01 |
| 28 (line 2) | 2300, CLM01 | Total charge for administration code |

Not Otherwise Classified & Compound Drugs

Not Otherwise Classified

- Use appropriate NOC code
 - J3490 – Unclassified drug
 - J3590 – Unclassified biological
 - J9999 – Not otherwise classified, anti-neoplastic drug
- Bill one service unit
 - 2400/SV1-04 data element or in line item 24G of CMS-1500 form
- Must enter information on line Item 19 of CMS-1500 or electronic equivalent
 - Name of the drug
 - Dose administered (mg, cc, etc.)
 - Route of administration (IV, IM, SC, PO, etc.)
 - Invoice price (for new drugs if WAC is unavailable, or for compounded drugs)

Compound Drugs – J7999

- Compound drugs
 - The process of combining or mixing two or more individual drugs to create a medication that is tailored to the needs of a specific patient
 - Examples - patient has allergies, cannot swallow a pill, cannot have dyes in their medications, etc.
 - Include the following in Item 19, or the electronic equivalent
 - Each drug name
 - Each drug dosage
 - Route of administration
 - Invoice price

Units of Drug/Biological

Units of Service

- Each drug/biological defines dosage amount in its description
 - For Medicare Part B billing purposes, the units of service on the claim for a drug/biological are entered in multiples of the units shown in the HCPCS narrative description
- Billing examples
 - [CMS IOM, Publication 100-04, Medicare Claims Processing Manual, Chapter 17, Section 70](#)

Unit of Service Example - LCD Article A52420

- [LCD Article A52420](#): Billing and Coding
- Hyaluronans Intra-articular Injections
 - Use drug code description to determine the correct units to submit on the claim:
 - "1mg" = total # of milligrams dosed
 - "per dose" = 1 unit, always

Billing Correct Units J7320 and J7322

- The number of units is calculated by milligrams; each unit being equal to one milligram
- J7320 – Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg
 - There are 25 mgs per dose; therefore each dose is 25 units
 - [Proper Billing Units for HCPCS J7320](#)
- J7322 – Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg
 - There are 24 mgs per dose; therefore each dose is 24 units

Billing Correct Units for Q2028

- Q2028 - Injection, Sculptra, 0.5 mg
- Sculptra is calculated as 0.5mg and is packaged as a single dose vial (SDV) containing 367.5mg per vial; and cannot be split up for payment
 - Each billing unit = 0.5 mg
 - One vial is 367.5 mg = 735 units
 - Two vials are 735 mg = 1470 units
- Depending on how many vials were administered, total quantity/units billed would be noted as the following: 735 or 1470

Discarded Drugs and Biologicals

Discarded Drugs and Biologicals

- Medicare Part B payment may be made for the unused portion of a **single dose vial** of a drug/biological
 - Medicare Part B will pay for the amount of the drug that was administered to the patient as well as the amount of the drug that has been discarded

Discarded Drugs and Biologicals

- **JW modifier** is used for discarded drugs or biologicals from single use vials or single use packages
- Append JW to the amount of drug or biological that is discarded, and bill it on a separate line item
- The discarded drug/biological must be documented in the patient's medical record

Discarded Drugs and Biologicals - Example

- A single use vial that is labeled to contain 100 units of a drug has 95 units administered to patient and five units discarded
 - 95 units is billed on one line
 - Five units is billed on a separate line using the JW modifier to identify as waste/discard

Proper Billing of Discarded Drugs and Biologicals

| 1500 Claim Field | ANSI 837 v5010 Loop & Segment | Information Required |
|------------------|---|--|
| 19 | 2300 or 2400, NTE02 May also use 2400, SV101-7 | NDC, invoice cost, dosage |
| 24D | 2400, SV101-2 | Appropriate drug procedure code |
| 24D | 2400, SV101-3 | JW modifier |
| 24G | 2400, SV104 | Units of service are calculated according to the applicable HCPCS code based on dosage |

Patient Supplied or Free-of-Charge Drugs

Patient Supplied or Free-of-Charge Drugs

- Charge for drug or biological must be included
 - Physician's bill
 - Cost of drug or biological must represent an expense to physician
- Drug code must be present on same claim
- Include appropriate information CMS-1500 claim form items or electronic equivalents

Proper Billing for Patient Supplied or Free-of-Charge Drugs

| 1500 Claim Form | ANSI 837 v5010 Loop, Segment, Element | Description |
|-----------------|---------------------------------------|---|
| 19 | 2300 or 2400, NTE, 02 | Narrative – Patient supplied or Provided Free of Charge |
| 24D (line 1) | 2400, SV1, 01-2 | Covered drug HCPCS code: <i>established or NOC drug code</i> |
| 24D (line 2) | 2400, SV1, 01-02 | Administration code |
| 28 (line 1) | 2300, CLM, 02 | Total charge = \$0.00 |
| 28 (line 2) | 2300, CLM, 02 | Total charge for administration code |

Self-Administered Drugs (SAD)

Self-Administered Drugs

- A drug that is self-administered by more than 50% of the Medicare beneficiary population is an exclusion to coverage
- CMS requires MACs to determine when a drug is excluded under SAD using instruction from
 - [CMS IOM Publication100-02, Medicare Benefit Policy Manual, Chapter 15, Section 50.2: Determining Self-Administration of Drug or Biological](#)

Self-Administered Drugs - Exclusions

- List of Medicare excluded drugs and biologicals
 - [Self-Administered Drug Exclusion List: Medical Policy Article \(A53021\)](#)
- Criteria used by NGS to determine SAD
 - [Process for Determining Self-Administered Drug Exclusions – Medical Policy Article \(A53020\)](#)

Proper Billing for Excluded SAD

| 1500 Claim Field | ANSI 837 v5010 – Loop & Segment | Information Required |
|------------------|---------------------------------|--|
| 24D (line 1) | 2400, SV101-2 | Drug HCPCS (<i>established code or NOC code</i>) |
| 24D (line 1) | 2400, SV101-3 | GY modifier |
| 24D (line 2) | 2400, SV101-2 | Administration code |
| 24D (line 2) | 2400, SV101-3 | GY modifier |
| 28 (line 1) | 2300, CLM02 | Total charge drug code=\$0.01 |
| 28 (line 2) | 2300, CLM02 | Total charge of administration code |

References

- [CMS IOM Publication 100-04, *Medicare Claims Processing Manual*, Chapter 17](#)
- Sections
 - 10 Payment Rules for Drugs and Biologicals
 - 20.1.3 Exceptions to Average Sales Price (ASP) Payment Methodology
 - 20.2 Single Drug Pricer (SDP)
 - 40 Discarded Drugs and Biologicals
 - 50 Assignment Required for Drugs and Biologicals
 - 70 Claims Processing Requirements – General
 - 80 Claim Processing for Special Drug Categories

References

- [CMS IOM Publication 100-02, *Medicare Benefit Policy Manual*, Chapter 15](#)
- Sections
 - 50 - 50.4.8 Drugs and Biologicals
 - 50.5 - 50.6 Self-Administered Drugs and Biologicals
- [CMS IOM Publication 100-04, *Medicare Claims Processing Manual*, Chapter 17](#)

References

- [Drugs and Biologicals- Coverage and Billing](#)
- [Local Coverage Determination \(LCD\): Drugs and Biologicals, Coverage of, for Label and Off-Label Uses \(L33394\)](#)
- [Drug Coverage under Different Parts of Medicare](#)
- MLN Matters® [*MM9603 Revised: JW Modifier: Drug Amount Discarded/Not Administered to any Patient*](#)
- [Medicare Program JW Modifier: Drug/Biological Amount Discarded/Not Administered To Any Patient Frequently Asked Questions](#)

Thank You!

- Follow-up email
 - Attendees will be provided a Medicare University Course Code
- Questions?

